ALK and neoplasm: In May 2020, following the IMpower110 (NCT02409342) clinical trial, the inclusion criteria of high PD-L1 expression ≥ 50% of tumor cells or ≥ 10% of tumor-infiltrating immune cells as defined by an FDA-approved device were approved for the treatment of adult metastatic NSCLC with no EGFR or ALK genomic aberrations (78).